A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer

Trial Profile

A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer

Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Enoblituzumab (Primary)
  • Indications Bladder cancer; Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors MacroGenics
  • Most Recent Events

    • 28 Sep 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2018.
    • 28 Sep 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018.
    • 10 Nov 2015 According to a MacroGenics media release, interim results of an ongoing Phase 1 dose-escalation study of enoblituzumab (MGA271) were presented in the late-breaking abstract session today at the 2015 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top